Medroxyprogesterone acetateSteroidal progestin CAS# 71-58-9 |
- Salmefamol
Catalog No.:BCC1919
CAS No.:18910-65-1
- Guanfacine hydrochloride
Catalog No.:BCC1609
CAS No.:29110-48-3
- (R,R)-Formoterol
Catalog No.:BCC1293
CAS No.:67346-49-0
- Doxazosin Mesylate
Catalog No.:BCC1257
CAS No.:77883-43-3
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 71-58-9 | SDF | Download SDF |
| PubChem ID | 6279 | Appearance | Powder |
| Formula | C24H34O4 | M.Wt | 386.52 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | Medroxyprogesterone 17-acetate; MPA | ||
| Solubility | DMSO : 10 mg/mL (25.87 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
| Chemical Name | [(6S,8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate | ||
| SMILES | CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C | ||
| Standard InChIKey | PSGAAPLEWMOORI-PEINSRQWSA-N | ||
| Standard InChI | InChI=1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Medroxyprogesterone acetate is a progestin, a synthetic variant of the human hormone progesterone and a potent progesterone receptor agonist.
Target: Progesterone Receptor
Medroxyprogesterone acetate(MPA) is a steroidal progestin, a synthetic variant of the human hormone progesterone. It is used as a contraceptive, in hormone replacement therapy and for the treatment of endometriosis as well as several other indications. MPA is a more potent derivative of its parent compound medroxyprogesterone (MP). While medroxyprogesterone is sometimes used as a synonym for medroxyprogesterone acetate, what is normally being administered is MPA and not MP [1, 2]. References: | |||||
Medroxyprogesterone acetate Dilution Calculator
Medroxyprogesterone acetate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.5872 mL | 12.9359 mL | 25.8719 mL | 51.7438 mL | 64.6797 mL |
| 5 mM | 0.5174 mL | 2.5872 mL | 5.1744 mL | 10.3488 mL | 12.9359 mL |
| 10 mM | 0.2587 mL | 1.2936 mL | 2.5872 mL | 5.1744 mL | 6.468 mL |
| 50 mM | 0.0517 mL | 0.2587 mL | 0.5174 mL | 1.0349 mL | 1.2936 mL |
| 100 mM | 0.0259 mL | 0.1294 mL | 0.2587 mL | 0.5174 mL | 0.6468 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Medroxyprogesterone acetate(MPA) is a steroidal progestin, a synthetic variant of the human hormone progesterone. It is used as a contraceptive, in hormone replacement therapy and for the treatment of endometriosis as well as several other indications. MP
- butanol
Catalog No.:BCN4976
CAS No.:71-36-3
- Cytosine
Catalog No.:BCN8533
CAS No.:71-30-7
- H-His-OH
Catalog No.:BCC2954
CAS No.:71-00-1
- 7,3',4'-Tri-O-methyleriodictyol
Catalog No.:BCN7766
CAS No.:70987-96-1
- 2-(5-Chloro-2-phenoxyphenyl)acetic acid
Catalog No.:BCC8481
CAS No.:70958-20-2
- SirReal2
Catalog No.:BCC6513
CAS No.:709002-46-0
- Dihydrocitflavanone
Catalog No.:BCN6873
CAS No.:70897-14-2
- (2S)-Isoxanthohumol
Catalog No.:BCN2892
CAS No.:70872-29-6
- Troxerutin
Catalog No.:BCN3828
CAS No.:7085-55-4
- Chlorothiazide Sodium
Catalog No.:BCC5628
CAS No.:7085-44-1
- Cyanidin-3-O-glucoside chloride
Catalog No.:BCN1230
CAS No.:7084-24-4
- Chicoric acid
Catalog No.:BCN1215
CAS No.:70831-56-0
- Veratridine
Catalog No.:BCC7515
CAS No.:71-62-5
- Digitoxin
Catalog No.:BCN5358
CAS No.:71-63-6
- Cathinone
Catalog No.:BCN1784
CAS No.:71031-15-7
- 1-Octacosanoyl glyceride
Catalog No.:BCN8190
CAS No.:71035-02-4
- Griselinoside
Catalog No.:BCN4272
CAS No.:71035-06-8
- 5,8,4'-Trihydroxy-7-methoxyflavone 8-O-glucoside
Catalog No.:BCN1372
CAS No.:710952-13-9
- MRS 2578
Catalog No.:BCC4976
CAS No.:711019-86-2
- Bucindolol
Catalog No.:BCC7444
CAS No.:71119-11-4
- Meloxicam (Mobic)
Catalog No.:BCC3808
CAS No.:71125-38-7
- (E)-3-Acetoxy-5-methoxystilbene
Catalog No.:BCN4273
CAS No.:71144-78-0
- (±)-Bay K 8644
Catalog No.:BCC3918
CAS No.:71145-03-4
- Leukotriene B4
Catalog No.:BCC7322
CAS No.:71160-24-2
Effects of depot-medroxyprogesterone acetate on the immune microenvironment of the human cervix and endometrium: implications for HIV susceptibility.[Pubmed:28051087]
Mucosal Immunol. 2017 Sep;10(5):1270-1278.
Depot-Medroxyprogesterone acetate is a commonly used injectable contraceptive that has been associated with an increased risk of HIV acquisition. This study compares effects of depot-Medroxyprogesterone acetate on immune parameters from several upper reproductive tract compartments relevant to HIV-1 susceptibility in repetitive samples from 15 depot-Medroxyprogesterone acetate users and 27 women not on hormonal contraceptives. Compared with samples from unexposed women in the mid-luteal phase, depot-Medroxyprogesterone acetate use was associated with: increased endocervical concentrations of MCP1 and IFNalpha2; decreased endocervical concentrations of IL1beta and IL6; increased proportions of endometrial CD4+ and CD8+ cells expressing the activation marker HLADR; increased density of endometrial macrophages; and decreased density of endometrial regulatory T cells. Unlike previous reports with samples from the vagina, we did not observe increased expression of the HIV co-receptor CCR5 on CD4+ T cells in the endocervix or endometrium. Our results indicate important differences in anatomic compartments regarding mechanisms by which depot-Medroxyprogesterone acetate could be associated with increased risk of HIV acquisition, including increased recruitment of macrophages to the endometrium, decreased levels of pro-inflammatory cytokines in the endocervix possibly leading to enhanced susceptibility to viral infection, and activation of endometrial T cells.
Genital Injury Signatures and Microbiome Alterations Associated With Depot Medroxyprogesterone Acetate Usage and Intravaginal Drying Practices.[Pubmed:28011908]
J Infect Dis. 2017 Feb 15;215(4):590-598.
Background: Increasing evidence suggests depot Medroxyprogesterone acetate (DMPA) and intravaginal practices may be associated with human immunodeficiency virus (HIV-1) infection risk; however, the mechanisms are not fully understood. This study evaluated the effect of DMPA and intravaginal practices on the genital proteome and microbiome to gain mechanistic insights. Methods: Cervicovaginal secretions from 86 Kenyan women, including self-reported DMPA users (n = 23), nonhormonal contraceptive users (n = 63), and women who practice vaginal drying (n = 46), were analyzed using tandem-mass spectrometry. Results: We identified 473 human and 486 bacterial proteins from 18 different genera. Depot Medroxyprogesterone acetate use associated with increased hemoglobin and immune activation (HBD, HBB, IL36G), and decreased epithelial repair proteins (TFF3, F11R). Vaginal drying associated with increased hemoglobin and decreased phagocytosis factors (AZU1, MYH9, PLAUR). Injury signatures were exacerbated in DMPA users who also practiced vaginal drying. More diverse (H index: 0.71 vs 0.45; P = .009) bacterial communities containing Gardnerella vaginalis associated with vaginal drying, whereas DMPA showed no significant association with community composition or diversity. Conclusions: These findings provide new insights into the impact of DMPA and vaginal drying on mucosal barriers. Future investigations are needed to confirm their relationship with HIV risk in women.
Effects of combined oral contraceptives, depot medroxyprogesterone acetate and the levonorgestrel-releasing intrauterine system on the vaginal microbiome.[Pubmed:27913230]
Contraception. 2017 Apr;95(4):405-413.
OBJECTIVES: Prior studies suggest that the composition of the vaginal microbiome may positively or negatively affect susceptibility to sexually transmitted infections (STIs) and bacterial vaginosis (BV). Some female hormonal contraceptive methods also appear to positively or negatively influence STI transmission and BV. Therefore, changes in the vaginal microbiome that are associated with different contraceptive methods may explain, in part, effects on STI transmission and BV. STUDY DESIGN: We performed a retrospective study of 16S rRNA gene survey data of vaginal samples from a subset of participants from the Human Vaginal Microbiome Project at Virginia Commonwealth University. The subset included 682 women who reported using a single form of birth control that was condoms, combined oral contraceptives (COCs), depot Medroxyprogesterone acetate (DMPA) or the levonorgestrel-releasing intrauterine system (LNG-IUS). RESULTS: Women using COCs [adjusted odds ratio (aOR) 0.29, 95% confidence interval (CI) 0.13-0.64] and DMPA (aOR 0.34, 95% CI 0.13-0.89), but not LNG-IUS (aOR 1.55, 95% CI 0.72-3.35), were less likely to be colonized by BV-associated bacteria relative to women who used condoms. Women using COCs (aOR 1.94, 95% CI 1.25-3.02) were more likely to be colonized by beneficial H2O2-producing Lactobacillus species compared with women using condoms, while women using DMPA (aOR 1.09, 95% CI 0.63-1.86) and LNG-IUS (aOR 0.74, 95% CI 0.48-1.15) were not. CONCLUSIONS: Use of COCs is significantly associated with increased vaginal colonization by healthy lactobacilli and reduced BV-associated taxa. IMPLICATIONS: COC use may positively influence gynecologic health through an increase in healthy lactobacilli and a decrease in BV-associated bacterial taxa.
High dose of green tea infusion normalized spiral artery density in rats treated with the depot-medroxyprogesterone acetate.[Pubmed:28163962]
J Intercult Ethnopharmacol. 2016 Oct 4;6(1):65-67.
AIM: The purpose of this study was to investigate the effects of green tea (GT) on the spiral artery density and endometrial thickness in female rats treated with the depot-Medroxyprogesterone acetate (DMPA). MATERIAL AND METHODS: A total of 24 female rats were randomly divided into four groups (n = 6 each): The control group (no treatment), the DMPA-treated group, treated with DMPA and GT doses of 165 mg/kg of body weight/day, and treated with DMPA and GT doses of 330 mg/kg of body weight/day. Spiral artery density and endometrial thickness were subjected to histopathological analysis. RESULTS: Spiral artery density decreased in the DMPA-treated group, despite the insignificant difference (P > 0.05). With regard to the administration of GT at doses of 165 and 330 mg/g of body weight/day, only GT at the high dose was capable of significantly preventing a decrease in spiral artery density (P < 0.05). At this dose, the spiral arteries achieved a density comparable to that of the control group (P > 0.05). Meanwhile, the administration of DMPA and/or DMPA with GT did not cause significant changes in endometrial thickness relative to the control group (P > 0.05). CONCLUSIONS: DMPA induced a decrease in spiral artery density, despite the insignificant differences, and these changes could be normalized by the administration of high doses of GT. Therefore, GT could be a candidate herb to prevent the adverse effects of the contraceptive DMPA.
